30characters is an AI-driven tool designed specifically to streamline the process of creating effective search ads. It assists in overcoming writer's block, aiding in the generation of high-quality headlines, descriptions among others with minimal input.
Expert Video Review by SEOGANT · March 2026
30 Characters is an AI-powered social media copywriting platform that helps marketers, content creators, and brand teams generate platform-optimized short-form copy for Twitter/X, LinkedIn, Instagram, and other social channels with the speed and volume required to maintain an active social presence across multiple platforms simultaneously.
The platform is built around the insight that social media content has specific format constraints and engagement mechanics that require specialized copywriting capability distinct from long-form content production.
The copy generation engine is trained on high-performing social content across different industries and brand voices, understanding the patterns that drive engagement on each platformhooks that stop the scroll on Twitter, professional insights that generate LinkedIn shares, and caption styles that complement different types of Instagram imagery.
Users input their topic, key message, and tone parameters, receiving multiple platform-appropriate copy options that can be published directly or customized further.
30 Characters integrates with social media scheduling and management tools, making it practical to move from content generation to scheduling within a single workflow rather than copying text between applications.
For brands managing active social presences across multiple platforms with small teams, the platform provides a practical solution to the volume and variety demands of social content production without sacrificing the quality and voice consistency that effective brand social media requires.
Get implementation playbooks for tools like 30characters in guided Academy lessons. Start free, then unlock the full library with Learner.
Open Academy →Pricing details on provider page.
Comments (0)
Sign in to join the discussion.